During the past decade, Fairfax Northern Virginia Hematology Oncology PC conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 10 clinical trials were completed, i.e. on average, 166.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 5 clinical trials were completed. i.e. 500% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fairfax Northern Virginia Hematology Oncology PC" #1 sponsor was "Novartis Pharmaceuticals" with 7 trials, followed by "Celgene" with 4 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Alliance for Clinical Trials in Oncology" with 2 trials sponsored and "Cephalon" with 2 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fairfax Northern Virginia Hematology Oncology PC" #1 collaborator was "ARMO BioSciences" with 2 trials as a collaborator, "National Cancer Institute (NCI)" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Helsinn Healthcare SA" with 1 trials as a collaborator and "Inova Health Care Services" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Fairfax Northern Virginia Hematology Oncology PC" are "Breast Cancer" (7 trials), "Multiple Myeloma" (4 trials), "Non Small Cell Lung Cancer" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials) and "Non-Small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Fairfax Northern Virginia Hematology Oncology PC" in a lesser frequency.

Most popular intervention types in "Fairfax Northern Virginia Hematology Oncology PC" are "Drug" (36 trials), "Biological" (5 trials), "Combination Product" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Paclitaxel" (4 trials), "gemcitabine hydrochloride" (3 trials), "Carboplatin" (2 trials) and "Lenalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Fairfax Northern Virginia Hematology Oncology PC" are 27 trials for "All" genders, 9 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Fairfax Northern Virginia Hematology Oncology PC". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Fairfax Northern Virginia Hematology Oncology PC, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Fairfax Northern Virginia Hematology Oncology PC, 3 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".